Mechanism, dosage tables, cycle structures, clinical data, reconstitution protocol, and COA-verified vendor pricing — everything in one place.
Sermorelin acetate is a synthetic 29-amino-acid peptide representing the N-terminal fragment of human growth hormone-releasing hormone (hGHRH). It binds GHRH receptors on pituitary somatotrophs and stimulates endogenous GH secretion, preserving the normal pulsatile GH release pattern and hypothalamic-pituitary-IGF-1 feedback axis.
| Property | Value |
|---|---|
| Class | GHRH analog |
| Sequence | GHRH(1-29)-NH₂ |
| Molecular weight | ~3,358 Da |
| Half-life | ~10–20 minutes (SubQ) |
| Peak GH response | 20–40 min post-injection |
| Route | Subcutaneous injection |
| Storage | Lyophilized: refrigerate; reconstituted: refrigerate, use within 30 days |
| Reconstitution | Bacteriostatic water |
| FDA status | Approved 1997 (Geref); discontinued commercially; research use |
Research protocols for sermorelin vary considerably based on the application. The following reflects data from clinical and observational literature — not a prescription or recommendation.
| Application | Dose Range | Frequency | Timing |
|---|---|---|---|
| GH deficiency (clinical) | 0.2–0.3 mcg/kg/day | Daily | Before bed |
| Anti-aging / somatopause | 200–300 mcg | Daily or 5 days on/2 off | Before bed |
| Body composition | 200–500 mcg | Daily | Before bed or post-workout |
| Diagnostic (GH stimulation test) | 1 mcg/kg IV | Single dose | Fasted morning |
Most protocols call for pre-sleep injection (30–60 minutes before bed) to amplify the largest natural GH pulse. Some researchers use a second injection in the morning or post-exercise to target different secretion windows.
Sermorelin is supplied as a lyophilized (freeze-dried) powder, typically in 2mg, 5mg, or 10mg vials. Reconstitute with bacteriostatic water (BAC water), injecting slowly along the vial wall to avoid agitation. Standard concentration: 2mg/2mL = 1mg/mL = 1,000 mcg/mL.
| Vial Size | BAC Water | Concentration | Volume per 200mcg dose |
|---|---|---|---|
| 2mg | 2mL | 1,000 mcg/mL | 0.20mL (20 units on U100 syringe) |
| 5mg | 2.5mL | 2,000 mcg/mL | 0.10mL (10 units on U100 syringe) |
| 10mg | 5mL | 2,000 mcg/mL | 0.10mL (10 units on U100 syringe) |
Unlike many peptides used in short acute protocols, sermorelin research tends toward longer cycles given its mechanism (stimulating endogenous GH rather than supplying it directly) and the gradual nature of GH-related adaptations.
Some researchers report tachyphylaxis (reduced response) with continuous daily use and prefer cycling. The 5/2 pattern is common in physician-supervised settings where receptor desensitization is a consideration.
Sermorelin is frequently studied alongside GHRP peptides (ipamorelin, hexarelin) for synergistic GH release. The GHRH + GHRP combination produces significantly greater GH output than either alone — this is well-documented in the literature.
Sermorelin has a more substantial clinical literature than most peptides in the research space, owing to its FDA-approved status. Key findings from the literature:
A series of studies in adult-onset GH deficiency demonstrated that sermorelin restored IGF-1 levels toward age-appropriate norms, with improvements in body composition (reduced fat mass, preserved lean mass) and self-reported quality of life over 6-month periods.
Age-related GH decline (somatopause) research has shown sermorelin can partially restore GH pulsatility in older subjects. Studies by Walker et al. demonstrated significant IGF-1 increases in subjects over 60 with daily subcutaneous dosing over 6 months.
Because GH is predominantly secreted during slow-wave sleep, sermorelin research has explored effects on sleep quality. Subjects in several protocols reported improved sleep depth, correlating with increases in measured GH during sleep studies.
The largest clinical dataset comes from pediatric use (the indication for which Geref was approved). Sermorelin produced comparable height velocity improvements to recombinant HGH in GH-deficient children in several comparative trials, with a favorable safety profile.
COA-verified vendor pricing, promo codes, and reconstitution guide.
View Pricing → Dosage CalculatorSermorelin is generally well-tolerated in the clinical literature. Reported adverse events from clinical trials and observational research include:
The side effect profile of sermorelin is generally considered more favorable than exogenous HGH, particularly regarding edema, carpal tunnel syndrome, and joint pain — which are more common with supraphysiological HGH levels.